Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
---|---|---|---|---|
2q36.1 | Craniofacial-deafness-hand syndrome | 122880 | AD | 3 |
Rhabdomyosarcoma 2, alveolar | 268220 | SMu | 3 | |
Waardenburg syndrome, type 1 | 193500 | AD | 3 | |
Waardenburg syndrome, type 3 | 148820 | AD, AR | 3 |
|
|
|
|
|
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
2q36.1 | Waardenburg syndrome, type 1 | 193500 | AD | 3 | PAX3 | 606597 |
Location | Phenotype | Inheritance |
Phenotype mapping key |
Phenotype MIM number |
Gene/Locus |
Gene/Locus MIM number |
---|---|---|---|---|---|---|
1p21-p13.3 | Waardenburg syndrome, type 2B | AD | 2 | 600193 | WS2B | 600193 |
2q36.1 | Waardenburg syndrome, type 1 | AD | 3 | 193500 | PAX3 | 606597 |
2q36.1 | Waardenburg syndrome, type 3 | AD, AR | 3 | 148820 | PAX3 | 606597 |
3p13 | Waardenburg syndrome, type 2A | AD | 3 | 193510 | MITF | 156845 |
8p23 | Waardenburg syndrome, type 2C | 2 | 606662 | WS2C | 606662 | |
12q21.32 | Waardenburg syndrome, type 2F | AR | 3 | 619947 | KITLG | 184745 |
13q22.3 | Waardenburg syndrome, type 4A | AD, AR | 3 | 277580 | EDNRB | 131244 |
20q13.32 | Waardenburg syndrome, type 4B | AD, AR | 3 | 613265 | EDN3 | 131242 |
22q13.1 | Waardenburg syndrome, type 4C | AD | 3 | 613266 | SOX10 | 602229 |
22q13.1 | Waardenburg syndrome, type 2E, with or without neurologic involvement | AD | 3 | 611584 | SOX10 | 602229 |
|
|
|
|
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM